Current issues in biowaivers and biosimilars
نویسندگان
چکیده
منابع مشابه
Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted joint mobility, chronic pain, fatigue, and functional disability, but also psychological distress. Direct health care costs represent about one-fourth of all costs and are prevalently represented by in-patient care expenditures. The introduction of biologics disease-modifying anti-rheumatic drugs...
متن کاملBiosimilars in oncology: current and future perspectives
The healthcare burden of cancer Cancer places a signifi cant, and growing, burden on healthcare systems around the world. Improved therapies and changing demographics are conspiring to increase the already considerable drain on resources. On the one hand, population growth and ageing will increase the number of new cancer cases in the coming years [1]; on the other, advances in diagnosis and ma...
متن کاملBiosimilars in Dermatology: Current Situation (Part I).
The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more biosimilars can be expected to follow in the coming months and years. Logically, this new situation will have economic repercussions and alter prescribing patterns among dermatologists. In this article, we review regulatory issues related to the ...
متن کاملEvolving policy issues in oncology: revisiting biosimilars and molecular testing.
Vanderbilt-Ingram Cancer Center (www.vicc.org) in Nashville, Tennessee, is one of a select few NCI–designated Comprehensive Cancer Centers in the southeastern United States and the only one in Tennessee that conducts research while providing care for both adult and pediatric patients. Established in 1993, Vanderbilt-Ingram brings together the cancer-related research, clinical care, prevention, ...
متن کاملBiomedical and Market Issues Surrounding the Advent of Biosimilars
As the patents associated with the biologics are set to expire in the near future, a new type of therapy appears on the horizon, and it is quite similar to the biologics. This commentary examines the biomedical and market issues surrounding the advent of biosimilars.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Clinical Pharmacology
سال: 2013
ISSN: 1751-2433,1751-2441
DOI: 10.1586/ecp.12.72